FOURIER OLE, estudios de COVID-19 y más, del cuarto día del ESC de 2022
Amgen Presents P-III (FOURIER) OLE Results of Repatha (evolocumab) for Atherosclerotic Cardiovascular Disease at ESC 2022, Published in Circulation
FOURIER-OLE, ulteriori riduzioni di eventi cardiovascolari nella t
FOURIER-OLE试验，长期应用依洛尤单抗可进一步降低心血管事件风险，且安全性和耐受性较好丨ESC 2022_腾讯新闻
FOURIER-OLE, ulteriori riduzioni di eventi cardiovascolari nella t
FOURIER Open Label Extension – TIMI STUDY GROUP
Evolocumab benefits outlined in Fourier-OLE • The Medical Republic
FOURIER-OLE
FOURIER-OLE
FOURIER-OLE
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease | Circulation
Evolocumab benefits build up in FOURIER OLE | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
Nikolay Novitskiy в Twitter: „RT @CMichaelGibson: FOURIER-OLE studies: In pts w/ stable ASCVD, long-term use of evolocumab with median follow-up of more than 7 yrs appea…“ / Twitter
Pablo Corral MD on Twitter: "#FOURIER-OLE program, 5️⃣ years later: ✓ Sustained LDLc ⬇️ ✓ Safety ✓ Greater impact on primary endpoint ✓ Cardiovascular ❤️mortality ☠️⬇️23% @society_eas @LipidosSal https://t.co/2b4QQQeqPe" / Twitter
FOURIER-OLE : l'Evolocumab suivi pendant presque 8 ans confirme la sécurité et l'efficacité sur la mortalité et les évènements cardiovasculaires, mais le retard n'est pas rattrapé
FOURIER-OLE
FOURIER-OLE: Long-Term Evolocumab Use Lowers CV Events, Including CV Mortality, in Atherosclerotic CVD - CRTonline
FOURIER-OLE
FOURIER-OLE: Long-term Safety of Evolocumab Therapy | Evolocumab
FOURIER and FOURIER OLE - YouTube
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease | Circulation
FOURIER-OLE: The Trial in Context | FOURIER-OLE
